AI Article Synopsis
- Acute respiratory distress syndrome (ARDS) is a severe condition marked by lung inflammation and low oxygen levels, leading to high rates of illness and death despite medical advancements.
- Hypoxia-inducible factor (HIF) is a critical protein that assists with important biological processes like metabolism, immune response, and cell growth, and its levels are typically regulated but can become stabilized during ARDS.
- This review emphasizes HIF's various roles in ARDS and explores its potential as a new therapeutic target in treating the syndrome.
Article Abstract
Acute respiratory distress syndrome (ARDS) is characterized by bilateral chest infiltration and acute hypoxic respiratory failure. ARDS carries significant morbidity and mortality despite advancements in medical management, calling for the development of novel therapeutic targets. Hypoxia-inducible factor (HIF) is a heterodimeric protein involved in various essential pathways, including metabolic reprogramming, immune modulation, angiogenesis and cell cycle regulation. HIF is routinely degraded in homeostasis conditions via the prolyl hydroxylase domain/von Hippel-Lindau protein pathway. However, HIF is stabilized in ARDS via various mechanisms (oxygen-dependent and independent) as an endogenous protective pathway and plays multifaceted roles in different cell populations. This review focuses on the functional role of HIF and its target genes during ARDS, as well as how HIF has evolved as a therapeutic target in current medical management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136894 | PMC |
| http://dx.doi.org/10.1113/JP284599 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!